Communication campaigns). Between August, 2010, and the ultimate end of 2011, over 155 million doses of QAACTs had been subsidised by AMFm. QAACT availability more than doubled in five countries and market share a lot more than doubled in four. The result of AMFm was even more limited in Madagascar and Niger, where AMFm ACT orders were lower. AMFm had an especially dramatic influence on the personal sector where QAACT marketplace share increased in all pilots, with the boost exceeding 30 %age factors in five of these. What is more, private for-revenue QAACT prices fell considerably in six countries, with the lower which range from US$1.28 to $4.82 per dose.